title: Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.
abstract: The 26S proteasome constitutes an essential degradation apparatus involved in the consistent recycling of misfolded and damaged proteins inside cells. The aberrant activation of the proteasome has been widely observed in various types of cancers and implicated in the development and progression of carcinogenesis. In the era of targeted therapies, the clinical use of proteasome inhibitors necessitates a better understanding of the molecular mechanisms of cell death responsible for their cytotoxic action, which are reviewed here in the context of sensitization of malignant gliomas, a tumor type particularly refractory to conventional treatments.
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Larissa, 41110, Greece. pvlacho@med.uth.gr
authors.forename: Panagiotis J
authors.initials: PJ
authors.lastname: Vlachostergios
authors.forename: Ioannis A
authors.initials: IA
authors.lastname: Voutsadakis
authors.forename: Christos N
authors.initials: CN
authors.lastname: Papandreou
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D001343:Autophagy / Q000502:physiology; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D009336:Necrosis / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000187:drug effects* / Q000378:metabolism; D061988:Proteasome Inhibitors / Q000627:therapeutic use*
chemical_list: D061988:Proteasome Inhibitors; D046988:Proteasome Endopeptidase Complex; C061553:ATP dependent 26S protease